title: [Therapeutic options in idiopathic chronic urticaria].
abstract: BACKGROUND
  Chronic idiopathic urticaria is a clinic entity that is manifested by wheals of more than six weeks of evolution, without identification of the causing agent, and sometimes resistant to conventional treatment. There are improvements with leukotriene receptor antagonists.
  
  
  OBJECTIVE
  To evaluate the clinical efficacy of montelukast and desloratadine individually and combined, compared with hydroxicine.
  
  
  METHODS
  The trial included 40 subjects with chronic idiopathic urticaria referred from the outpatient allergy service. They were randomly divided into four groups to receive: hydoxicine, montelukast, montelukast plus desloratadine, and desloratadine alone during six weeks. The assessments compared the first and sixth weeks.
  
  
  RESULTS
  All therapeutic options are effective, with statistical significance, highlighting that the new therapeutic modes are safe and have better resolution of lesions and symptoms.
  
  
  CONCLUSIONS
  All the alternatives are viable, considering they are adjusted to each patient, adverse symptoms, socio-economic status and clinical severity.
authors.affiliation: Servicio de alergia e inmunología clinica, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS.
authors.forename: Patricia Montero
authors.initials: PM
authors.lastname: Mora
authors.forename: Maria del Carmen
authors.initials: Mdel C
authors.lastname: González Pérez
authors.forename: Margarita
authors.initials: M
authors.lastname: Jiménez Villarruel
authors.forename: Eduardo
authors.initials: E
authors.lastname: Rodriguez Castro
authors.forename: Guillermo Guidos
authors.initials: GG
authors.lastname: Fogelbach
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000799:Angioedema / Q000188:drug therapy*; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000982:Antipruritics / Q000008:administration & dosage / Q000627:therapeutic use; D002908:Chronic Disease; D003521:Cyclopropanes; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use*; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D017336:Loratadine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D013440:Sulfides; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D000085:Acetates; D018926:Anti-Allergic Agents; D000982:Antipruritics; D003521:Cyclopropanes; D006634:Histamine H1 Antagonists; D039563:Histamine H1 Antagonists, Non-Sedating; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D006919:Hydroxyzine; D017336:Loratadine; C121345:desloratadine; C093875:montelukast